Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Treatment enhances ultradian rhythms of CSF monoamine metabolites in patients with major depressive episodes.

Salomon RM, Kennedy JS, Johnson BW, Urbano Blackford J, Schmidt DE, Kwentus J, Gwirtsman HE, Gouda JF, Shiavi RG.

Neuropsychopharmacology. 2005 Nov;30(11):2082-91.

2.

Central neurochemical ultradian variability in depression.

Salomon RM, Johnson BW, Schmidt DE.

Dis Markers. 2006;22(1-2):65-72.

3.

Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers.

De Bellis MD, Geracioti TD Jr, Altemus M, Kling MA.

Biol Psychiatry. 1993 Apr 15-May 1;33(8-9):636-41.

PMID:
7687151
4.

Analysis of equine cisterna magna cerebrospinal fluid for the presence of some monoamine neurotransmitters and transmitter metabolites.

Vaughn DM, Smyth GB, Whitmer WL, Satjawatcharaphong C.

Vet Res Commun. 1989;13(3):237-49.

PMID:
2476887
5.

Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients.

Carpenter LL, Moreno FA, Kling MA, Anderson GM, Regenold WT, Labiner DM, Price LH.

Biol Psychiatry. 2004 Sep 15;56(6):418-26.

PMID:
15364040
6.
7.

Polyunsaturated fatty acid associations with dopaminergic indices in major depressive disorder.

Sublette ME, Galfalvy HC, Hibbeln JR, Keilp JG, Malone KM, Oquendo MA, Mann JJ.

Int J Neuropsychopharmacol. 2014 Mar;17(3):383-91. doi: 10.1017/S1461145713001399. Epub 2013 Dec 3.

9.
10.

Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response.

Nikisch G, Mathé AA, Czernik A, Eap CB, Jiménez-Vasquez P, Brawand-Amey M, Baumann P.

J Clin Psychopharmacol. 2004 Jun;24(3):283-90.

PMID:
15118482
11.

Monoamine metabolites level in CSF is related to the 5-HTT gene polymorphism in treatment-resistant depression.

Kishida I, Aklillu E, Kawanishi C, Bertilsson L, Agren H.

Neuropsychopharmacology. 2007 Oct;32(10):2143-51. Epub 2007 Feb 14.

12.

Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid.

Blennow K, Wallin A, Gottfries CG, Månsson JE, Svennerholm L.

J Neural Transm Park Dis Dement Sect. 1993;5(1):5-15.

PMID:
7679905
13.

Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease.

Poceta JS, Parsons L, Engelland S, Kripke DF.

Sleep Med. 2009 Jan;10(1):129-33. doi: 10.1016/j.sleep.2007.11.002. Epub 2008 Jan 22.

PMID:
18207455
14.
15.

Reduced cerebrospinal HVA concentrations and HVA/5-HIAA ratios in suicide attempters. Monoamine metabolites in 120 suicide attempters and 47 controls.

Engström G, Alling C, Blennow K, Regnéll G, Träskman-Bendz L.

Eur Neuropsychopharmacol. 1999 Sep;9(5):399-405.

PMID:
10523046
16.

Uncoupling of serotonergic and noradrenergic systems in depression: preliminary evidence from continuous cerebrospinal fluid sampling.

Geracioti TD Jr, Loosen PT, Ekhator NN, Schmidt D, Chambliss B, Baker DG, Kasckow JW, Richtand NM, Keck PE Jr, Ebert MH.

Depress Anxiety. 1997;6(3):89-94.

PMID:
9442982
17.

Cerebrospinal fluid monoamine metabolite concentrations as intermediate phenotypes between glutamate-related genes and psychosis.

Andreou D, Söderman E, Axelsson T, Sedvall GC, Terenius L, Agartz I, Jönsson EG.

Psychiatry Res. 2015 Sep 30;229(1-2):497-504. doi: 10.1016/j.psychres.2015.06.023. Epub 2015 Jun 27.

18.

CSF monoamine metabolites of depressed patients during illness and after recovery.

Träskman-Bendz L, Asberg M, Bertilsson L, Thorén P.

Acta Psychiatr Scand. 1984 Apr;69(4):333-42.

PMID:
6202099
19.

Continuous covariability of dopamine and serotonin metabolites in human cerebrospinal fluid.

Geracioti TD Jr, Keck PE Jr, Ekhator NN, West SA, Baker DG, Hill KK, Bruce AB, Wortman MD.

Biol Psychiatry. 1998 Aug 1;44(3):228-33.

PMID:
9693394
20.

The dopamine-serotonin relationship in clozapine response.

Szymanski S, Lieberman J, Pollack S, Munne R, Safferman A, Kane J, Kronig M, Cooper T.

Psychopharmacology (Berl). 1993;112(1 Suppl):S85-9.

PMID:
7530378

Supplemental Content

Support Center